Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.

You may also be interested in...

Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA

"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.

FDA Will Release Follow-On Biologics Background Document By Year-End

The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts